C3orf33 Inhibitors
C3orf33 inhibitors encompass a range of chemical compounds that indirectly lead to the diminishment of C3orf33's functional activity by influencing specific signaling pathways and cellular processes. MEK inhibitors PD 98059 and U0126 impede the MEK/ERK pathway, which potentially reduces C3orf33 activity if it is modulated by this pathway. PI3K inhibitors LY 294002 and Wortmannin, along with the mTOR inhibitor Rapamycin, disrupt the PI3K/Akt and mTOR signaling respectively, pathways that could be imperative for C3orf33's function, thus indirectly decreasing its activity. The Rho kinase inhibitor Y-27632 and the PKC inhibitor Gö 6983 would reduce C3orf33's activity if it is regulated by the Rho/ROCK or PKC pathways. Inhibition by these compounds suggests a complex regulatory network where C3orf33 is modulated by multiple kinases and signaling molecules.
In addition to these, the p38 MAPK inhibitor SB 203580, the JNK inhibitor SP600125, and the Src family kinase inhibitor PP 2 target other major signaling pathways that might control C3orf33 activity. NF449, as a Gs-alpha subunit inhibitor, could also lead to reduced C3orf33 activity by perturbing G-protein coupled receptor signaling. Lastly, the calcium chelator BAPTA/AM indirectly diminishes C3orf33's activity by affecting calcium-dependent signaling pathways, which are crucial for numerous cellular functions. The collective impact of these inhibitors on the functional activity of C3orf33 highlights the intricate web of intracellular signaling required for its regulation, assuming that C3orf33 is indeed influenced by these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which disrupts the MEK/ERK pathway. By inhibiting this pathway, PD 98059 indirectly diminishes the functional activity of C3orf33, assuming C3orf33 is downstream of ERK and is regulated by it. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K, leading to the suppression of the PI3K/Akt signaling pathway. By inhibiting PI3K, LY 294002 indirectly decreases the functional activity of C3orf33 if C3orf33 activity is PI3K/Akt-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which diminishes the p38 MAPK signaling pathway. If C3orf33 is a part of this signaling route, its functional activity would be indirectly reduced by SB 203580. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a crucial component of the PI3K/Akt/mTOR pathway. Inhibition of this pathway by Rapamycin would lead to a decrease in C3orf33 activity if C3orf33 is regulated by mTOR signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a Rho-associated protein kinase inhibitor that disrupts the Rho/ROCK pathway. If C3orf33 is influenced by Rho/ROCK signaling, Y-27632 would indirectly reduce its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and indirectly inhibits the ERK pathway. If C3orf33 operates downstream of ERK or is regulated by it, its activity would be diminished by U0126. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a Jun N-terminal kinase inhibitor, targeting the JNK signaling pathway. This inhibition can lead to decreased activity of C3orf33 if it is part of the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, and by suppressing the PI3K/Akt pathway, it would indirectly diminish the activity of C3orf33 if the protein is PI3K/Akt pathway-dependent. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha subunit of G-proteins, thus can disrupt G-protein coupled receptor signaling. If C3orf33 is regulated by GPCR pathways, NF449 would indirectly reduce its activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a pan-PKC inhibitor, which affects the PKC-dependent pathways. The functional activity of C3orf33 would be indirectly decreased by Gö 6983 if C3orf33 relies on PKC signaling. | ||||||